Corrigendum: Case report: A sustained survival benefit of third-line immunotherapy for refractory thymic carcinoma

Front Oncol. 2024 Dec 2:14:1516024. doi: 10.3389/fonc.2024.1516024. eCollection 2024.

Authors

Mi Meng^#¹, Bo Yu^#², Jie Luo³, Yuju Bai¹, Lin Li¹, Shicheng Chen², Sisi He¹, Hu Ma¹

Affiliations

¹ Department of Thoracic Oncology, The second Affiliated Hospital of Zunyi Medical University, Zunyi, China.
² Department of Urology, The second Affiliated Hospital of Zunyi Medical University, Zunyi, China.
³ Department of Radiation Oncology, Guiqian International General Hospital, Guiyang, China.

^# Contributed equally.

Abstract

[This corrects the article DOI: 10.3389/fonc.2024.1326006.].

Keywords: anti-PD-1; case report; sintilimab; therapeutic option; thymic carcinoma(TC).

Copyright © 2024 Meng, Yu, Luo, Bai, Li, Chen, He and Ma.

Publication types

Published Erratum